论文部分内容阅读
目的评价孟鲁司特钠联合转移因子治疗儿童支气管哮喘的临床疗效。方法将周口市川汇区妇幼保健院2008年10月—2011年3月收治的62例轻中度支气管哮喘患儿随机分为治疗组和对照组各31例,对照组口服孟鲁司特片5mg,每晚1次;治疗组在对照组治疗的基础上加用转移因子口服液10ml/次,2次/d,两组均治疗6个月后评价疗效。结果治疗组和对照组总有效率分别为96.8%、83.9%,差异有统计学意义(P<0.05)。结论孟鲁司特钠与转移因子联合用药能较好地控制临床症状,不良反应轻微,使患者生活质量明显提高。
Objective To evaluate the clinical efficacy of montelukast combined with transfer factor in children with bronchial asthma. Methods 62 cases of mild to moderate bronchial asthma in Chuanhui District Maternal and Child Health Hospital from October 2008 to March 2011 were randomly divided into treatment group (31 cases) and control group (31 cases). The control group received montelukast tablets , Once a night; treatment group in the control group based on the treatment with transfer factor oral solution 10ml / time, 2 times / d, both groups were treated for 6 months after the evaluation of the effect. Results The total effective rates of the treatment group and the control group were 96.8% and 83.9%, respectively, with significant difference (P <0.05). Conclusion The combination of montelukast sodium and transfer factor can better control the clinical symptoms with mild adverse reactions and improve the quality of life of the patients.